Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-1-associated dementia: a basic science and clinical perspective.

Thomas S Diesing1, Susan Swindells, Harris Gelbard

  • 1Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

The AIDS Reader
|September 17, 2002
PubMed
Summary

HIV-1 associated dementia (HAD) is a brain disorder caused by the virus. While treatments have reduced its occurrence, cognitive issues persist in many HIV patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerated amyloid neurodegeneration in HIV-1-infected APP-KI Alzheimer's disease mice.

bioRxiv : the preprint server for biology·2026
Same author

CAR Treg therapies for neurodegenerative diseases.

iScience·2026
Same author

A Hypothesis-Generating Pharmacologic Profile for Sargramostim Treatment of Parkinson's Disease.

Cellular and molecular neurobiology·2026
Same author

Colostrum extracellular vesicles are neuroprotective in models of Parkinson's disease.

Theranostics·2026
Same author

An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail.

Nature communications·2026
Same author

Extracellular vesicle-based therapies for neurodegenerative diseases.

NeuroImmune pharmacology and therapeutics·2026

Area of Science:

  • Neuroscience
  • Immunology
  • Virology

Background:

  • HIV-1 associated dementia (HAD) is a metabolic encephalopathy.
  • It is driven by immune activation of brain mononuclear phagocytes, including macrophages and microglia.
  • These cells are also reservoirs for persistent HIV infection and sources of neurotoxins.

Purpose of the Study:

  • To summarize the pathogenesis and clinical manifestations of HAD.
  • To discuss the impact of current therapies on HAD incidence and morbidity.

Main Methods:

  • Review of existing literature on HIV-1 associated dementia.
  • Analysis of the role of viral infection and immune activation in neurological impairment.
  • Examination of the effects of antiretroviral and adjunctive therapies.

Related Experiment Videos

Main Results:

  • Cognitive, behavioral, and motor abnormalities characterize HAD.
  • Neurologic impairments are linked to CD4+ T lymphocyte depletion and high viral loads.
  • Therapeutic advancements have decreased HAD incidence.

Conclusions:

  • Despite improved therapies, cognitive dysfunction remains a significant cause of morbidity in people with HIV.
  • Understanding the mechanisms of HAD is crucial for developing effective treatments.